La Vie Health and Virotek Biosciences Partner to Advance the Next Generation of Precision Health
Ontario and Richmond Hill, Ontario--(Newsfile Corp. - September 15, 2026) - La Vie Health ("La Vie") and Virotek Biosciences ("Virotek") today announced a strategic collaboration to integrate advanced genomic insights into La Vie's broader physician-led preventative, precision and healthspan model. This partnership advances both companies' commitment to precision health, with Virotek adding a clinically contextualized genomic layer to La Vie's comprehensive precision-health prog
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-15 8:30 AM EDT | Virotek Biosciences Inc.
Adia Med Submits Fifth 2026 Clinical Study to IRB: Osteoarthritis Protocol for One-Time Systemic Treatment
Winter Park, Florida--(Newsfile Corp. - September 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted a clinical study protocol to an Institutional Review Board for review and approval. The proposed study is designed to evaluate a one-time systemic treatment with AdiaVita, the Company's umbilical cord blood-derived stem cell and exosome product, in adults with osteoarthritis. Participa
Soins de santé et hôpitaux, Santé
2026-09-15 8:00 AM EDT | Adia Med Inc.
Extendicare Announces September 2026 Dividend of C$0.0441 per Share
Markham, Ontario--(Newsfile Corp. - September 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of September 2026, which is payable on October 15, 2026 to shareholders of record at the close of business on September 30, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-15 8:00 AM EDT | Extendicare Inc.
Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness Therapy
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce that its wholly owned subsidiary, Filament Health Corp. ("Filament"), has entered into a supply and licensing agreement with the University of Southern California, on behalf of its Keck School of Medicine of USC, for t
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-09-15 7:59 AM EDT | Rhelion Life Sciences Corp.
naia Relief Inc. Announces Commencement of Trading on the TSX Venture Exchange Under the Symbol "NAIA" and Engages Independent Trading Group as Market Maker
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - naia Relief Inc. (TSXV: NAIA) ("naia Relief" or the "Company") is pleased to announce that its common shares have been approved for listing on the TSX Venture Exchange (the "TSXV") and will commence trading under the symbol "NAIA" effective September 15, 2026. The listing marks an important milestone in the Company's evolution and establishes naia Relief Inc. as a publicly traded company positioned to advance its growth st
2026-09-15 7:00 AM EDT | Naia Relief Inc.
BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 15, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE:
Biotechnologies, Pharmaceutique, Santé
2026-09-15 7:00 AM EDT | BioHarvest Sciences Inc.
Holy Crap Foods to Exhibit at CHFA NOW Toronto, Debuting New Protein SKUs and Interactive AI Photo Experience
Vancouver, British Columbia--(Newsfile Corp. - September 15, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"), will be exhibiting at the CHFA NOW Toronto trade show on September 26 and 27, 2026, at Exhibition Place in Toronto, Ontario. CHFA NOW Toronto is one of Canada's premier trade events for the natural, organic, and wellne
2026-09-15 6:00 AM EDT | Restart Life Sciences Corp.
Edison Issues Report on Severfield (SFR)
London, United Kingdom--(Newsfile Corp. - September 15, 2026) - Edison issues report on Severfield (LSE: SFR). Severfield is the market leader in the design, fabrication and construction of structural steel in the UK and Europe. Its FY26 results in June were in line with market expectations and accompanied by a refreshed strategy, which was clearly articulated and supported by new medium-term ambitions, including underlying operating margins of 7-8% and £40-50m of underlying PBT. M
Services bancaires / financiers, Matériel informatique, Logiciels, Santé
2026-09-15 3:38 AM EDT | Edison Group
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Toronto, Ontario--(Newsfile Corp. - September 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and re
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-09-14 7:53 AM EDT | Rhelion Life Sciences Corp.
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that, following the formal completion of the Phase 1b clinical study, it has submitted a meeting request and comprehensive briefing package to the U.S. Food and Drug Administration (FDA).
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-14 7:00 AM EDT | Phio Pharmaceuticals Corp.
Beckett's Announces Results of Its 2026 Annual and Special Meeting of Shareholders and the Granting of Stock Options
Ontario and Los Angeles, California--(Newsfile Corp. - September 14, 2026) - Beckett's Inc. (CSE: BKTS) ("Beckett's" or the "Company") announces that all items of business were approved by shareholders at the Company's Annual and Special Meeting of shareholders held on September 10, 2026. All five proposed director nominees were elected by shareholders. Shareholders also voted in favour of the re-appointment of Zeifmans LLP as the Company's auditor for the ensuing
Aliments / boissons, Cannabis, Santé
2026-09-14 7:00 AM EDT | Becketts Inc.
Promino Holds Rejuvenate Muscle Health(TM) U.S. Retail Pricing as Whey Protein Costs Remain at Record Levels
WPC80 whey pricing has increased more than fivefold since 2023, reaching approximately US$14.50/lb in 2026 Rejuvenate remains US$24.99 for 14 servings and US$39.99 for 30 servings at U.S. retail — as much as 40% lower per serving than a current leading 2-lb whey benchmark Published human research supports the ability of a low-dose leucine-rich essential amino acid formulation to stimulate muscle protein synthesis compa
Aliments / boissons, Sports, Santé
2026-09-14 7:00 AM EDT | Promino Nutritional Sciences, Inc.
BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 14, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-1
Biotechnologies, Pharmaceutique, Santé
2026-09-14 7:00 AM EDT | BioHarvest Sciences Inc.
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce today that it has filed a final short form prospectus (the "Final Prospectus") with the securities regulatory authorities in the provinces of British
2026-09-11 7:45 PM EDT | BetterLife Pharma Inc.
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte Ne
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-11 9:00 AM EDT | Phio Pharmaceuticals Corp.
Naia Relief Announces Conditional Approval for Listing on the TSX Venture Exchange and Commencement of Trading
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - Naia Relief Inc. (the "Company" or "Naia Relief") is pleased to announce that it has received conditional approval of the TSX Venture Exchange ("TSXV") to list its common shares on the TSXV. The Company's common shares will commence trading on the TSXV under the symbol "NAIA", effective market open on September 15, 2026. In addition, further to the Company's press release of September 8, 2026, an a
2026-09-11 7:00 AM EDT | Naia Relief Inc.
Psyched Wellness Announces Secured Term Loan
Toronto, Ontario--(Newsfile Corp. - September 10, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, announces that it has entered into secured term notes (the "Notes") with Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P. (together the "Lenders") for an aggregat
Cannabis, Santé, Psychédéliques, Producteurs de cannabis
2026-09-10 4:15 PM EDT | Psyched Wellness Ltd.
DiagnosTear Announces Positive Final Results from Clinical Study Demonstrating Strong Diagnostic Performance of TeaRx(TM) Red Eye for Detecting Total Tear IgE as a Biomarker for Allergic conjunctivitis
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, is pleased to announce positive final results from its clinical study conducted with AlyaTec for TeaRx™ Red Eye further to the Company's press releases dated December 2, 2025, February 26, 2026, and July 9, 2026. The final results were obtained and analysed from 93 tear sa
2026-09-10 8:30 AM EDT | DiagnosTear Technologies Inc.
Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
Toronto, Ontario--(Newsfile Corp. - September 10, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic se
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-09-10 7:55 AM EDT | Rhelion Life Sciences Corp.
MD Hyperbaric Appoints Renowned Hyperbaric Researcher Dr. Amir Hadanny as Chief Medical Officer
New York, New York--(Newsfile Corp. - September 9, 2026) - MD Hyperbaric, one of the fastest-growing hyperbaric oxygen therapy (HBOT) networks in the United States, announced the appointment of Amir Hadanny, MD, as Chief Medical Officer. Dr. Hadanny is a neurosurgeon and hyperbaric physician and one of the most published clinical researchers in hyperbaric medicine, with more than 80 peer-reviewed publications. In this role,
Soins de santé et hôpitaux, Santé
2026-09-09 9:00 AM EDT | MD Hyperbaric